Analysts Set CytomX Therapeutics, Inc. (NASDAQ:CTMX) PT at $5.77

Shares of CytomX Therapeutics, Inc. (NASDAQ:CTMX - Get Free Report) have been assigned an average rating of "Moderate Buy" from the six research firms that are presently covering the stock, MarketBeat reports. Three research analysts have rated the stock with a hold rating and three have issued a buy rating on the company. The average twelve-month target price among analysts that have covered the stock in the last year is $5.77.

Separately, HC Wainwright reissued a "neutral" rating on shares of CytomX Therapeutics in a research report on Friday, September 13th.

Hedge Funds Weigh In On CytomX Therapeutics

A number of large investors have recently made changes to their positions in CTMX. US Bancorp DE bought a new position in shares of CytomX Therapeutics in the third quarter worth $40,000. SG Americas Securities LLC bought a new position in shares of CytomX Therapeutics in the first quarter worth $57,000. XTX Topco Ltd boosted its holdings in shares of CytomX Therapeutics by 382.6% in the second quarter. XTX Topco Ltd now owns 60,586 shares of the biotechnology company's stock worth $74,000 after acquiring an additional 48,033 shares during the period. Forefront Analytics LLC boosted its holdings in shares of CytomX Therapeutics by 206.7% in the second quarter. Forefront Analytics LLC now owns 64,065 shares of the biotechnology company's stock worth $78,000 after acquiring an additional 43,176 shares during the period. Finally, Cubist Systematic Strategies LLC boosted its holdings in shares of CytomX Therapeutics by 96.6% in the second quarter. Cubist Systematic Strategies LLC now owns 82,054 shares of the biotechnology company's stock worth $100,000 after acquiring an additional 40,309 shares during the period. 67.77% of the stock is owned by institutional investors.

CytomX Therapeutics Stock Performance

Shares of CTMX remained flat at $1.00 on Thursday. The company had a trading volume of 395,435 shares, compared to its average volume of 2,594,855. The firm has a market capitalization of $77.58 million, a PE ratio of 4.98 and a beta of 1.04. The business has a 50-day moving average price of $1.16 and a 200 day moving average price of $1.50. CytomX Therapeutics has a one year low of $0.99 and a one year high of $5.85.

CytomX Therapeutics (NASDAQ:CTMX - Get Free Report) last released its earnings results on Thursday, August 8th. The biotechnology company reported ($0.08) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.07) by ($0.01). CytomX Therapeutics had a negative return on equity of 27.44% and a net margin of 9.27%. The firm had revenue of $25.12 million during the quarter, compared to analysts' expectations of $21.79 million. During the same period in the prior year, the business earned ($0.02) earnings per share. As a group, analysts forecast that CytomX Therapeutics will post -0.29 earnings per share for the current year.

About CytomX Therapeutics

CytomX Therapeutics, Inc, an oncology-focused biopharmaceutical company, focuses on developing novel conditionally activated biologics localized to the tumor microenvironment. The company utilizes conditional activation platform technology for oncology biologics research and development comprising the validation of targets for antibody-drug conjugates (ADCs), opening therapeutic window for novel T-cell engagers (TCEs) targeting solid tumors, and increasing the therapeutic index for immune modulators, such as cytokines; and PROBODY platform in preclinical research in areas outside of oncology.